STAAR Surgical Company has provided an update regarding its agreement with Alcon, under which Alcon will acquire STAAR for $30.75 per share in cash, representing a 74% premium to the 90-day volume-weighted average price. In communications following the agreement, STAAR clarified that although several parties expressed vague interest prior to the announcement, none submitted a proposal or pursued due diligence during the go-shop period. Additionally, a party believed to be FountainVest initiated contact late in the process but ultimately declined to execute a nondisclosure agreement even after STAAR accepted its requested changes. No alternative proposals were received before the go-shop period expired. The company reiterated that Alcon’s offer represents certain and immediate cash value for STAAR’s shareholders. A virtual Special Meeting of Stockholders has been scheduled for December 19, 2025, to consider the transaction.